Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
- Revenue in GBP (TTM)3.55m
- Net income in GBP39.39m
- Incorporated2015
- Employees56.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hVIVO PLC | 62.73m | 10.65m | 70.42m | 301.00 | 6.62 | 1.56 | 4.96 | 1.12 | 0.0155 | 0.0155 | 0.0911 | 0.0657 | 0.7289 | -- | 4.20 | 208,388.70 | 12.38 | 5.51 | 20.28 | 10.35 | -- | -- | 16.98 | 6.73 | 1.86 | -- | 0.2241 | 67.09 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Scancell Holdings Plc | 0.00 | -15.81m | 107.83m | 61.00 | -- | -- | -- | -- | -0.0171 | -0.0171 | 0.00 | -0.015 | 0.00 | -- | -- | 0.00 | -81.40 | -31.66 | -625.06 | -37.66 | -- | -- | -- | -822.37 | -- | -42.23 | 251.00 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Avacta Group Plc | 11.26m | -29.43m | 121.86m | 151.00 | -- | 12.54 | -- | 10.82 | -0.085 | -0.1496 | 0.0327 | 0.0251 | 0.1854 | 0.00 | 2.64 | 74,576.16 | -48.46 | -43.48 | -172.33 | -78.27 | 44.59 | 63.54 | -261.32 | -781.44 | 1.08 | -0.5712 | 0.7229 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Bioventix PLC | 13.66m | 7.85m | 140.03m | 17.00 | 18.09 | 12.40 | 17.60 | 10.25 | 1.48 | 1.48 | 2.58 | 2.16 | 1.04 | 2.17 | 2.21 | 803,738.30 | 59.98 | 58.33 | 69.06 | 63.62 | 90.95 | 93.09 | 57.42 | 64.12 | 6.69 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| 4Basebio PLC | 933.00k | -12.33m | 155.09m | -- | -- | 5.87 | -- | 166.23 | -0.9391 | -0.9391 | 0.0711 | 1.70 | 0.0329 | 0.8584 | 4.78 | -- | -43.54 | -36.81 | -48.26 | -40.98 | 67.52 | 69.88 | -1,321.87 | -1,160.83 | 11.18 | -19.68 | 0.3658 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -22.37m | 241.30m | 25.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -0.0805 | 0.00 | -- | -- | 0.00 | -227.96 | -227.46 | -- | -1,738.54 | -- | -- | -- | -- | -- | -2.58 | 5.15 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Puretech Health PLC | 3.55m | 39.39m | 307.92m | 56.00 | 7.30 | 1.00 | 13.34 | 86.64 | 0.1753 | 0.1753 | 0.0139 | 1.28 | 0.0075 | -- | 2.48 | 63,463.20 | 4.29 | -3.27 | 4.57 | -3.83 | -- | -- | 575.43 | -253.25 | -- | -- | 0.052 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Oxford BioMedica plc | 128.80m | -43.19m | 364.58m | 861.00 | -- | 6.38 | -- | 2.83 | -0.414 | -0.414 | 1.24 | 0.5384 | 0.5322 | 5.73 | 4.71 | 149,590.00 | -20.09 | -20.23 | -25.99 | -25.48 | 41.17 | 49.36 | -37.74 | -45.03 | 2.05 | -5.42 | 0.6426 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Allergy Therapeutics plc | 55.66m | -35.65m | 386.08m | 602.00 | -- | -- | -- | 6.94 | -0.0075 | -0.0075 | 0.0117 | -0.0015 | 0.7836 | 2.15 | 6.00 | 92,453.49 | -50.19 | -22.88 | -78.92 | -30.15 | 54.04 | 66.47 | -64.05 | -24.88 | 1.15 | -4.07 | 1.19 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Genus plc | 671.60m | -4.00m | 1.41bn | 3.44k | -- | 2.72 | 35.70 | 2.09 | -0.0612 | -0.0612 | 10.16 | 7.82 | 0.6585 | -- | 6.11 | 195,289.30 | -0.6275 | 3.30 | -0.7199 | 3.87 | -- | -- | -0.953 | 4.98 | 1.33 | -- | 0.3656 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management Ltd.as of 07 Apr 2025 | 40.99m | 17.07% |
| Lansdowne Partners (UK) LLPas of 31 Mar 2024 | 21.89m | 9.11% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 20.81m | 8.66% |
| Jupiter Asset Management Ltd.as of 15 Jul 2020 | 14.25m | 5.93% |
| Citigroup Global Markets, Inc. (Investment Management)as of 23 May 2025 | 12.25m | 5.10% |
| Miller Value Partners LLCas of 31 Mar 2021 | 10.04m | 4.18% |
| Patient Capital Management, Inc.as of 31 Mar 2023 | 9.81m | 4.08% |
| Eurizon Capital SGR SpAas of 02 Jun 2025 | 9.56m | 3.98% |
| The Vanguard Group, Inc.as of 07 Apr 2025 | 7.85m | 3.27% |
| Strategic Advisers LLCas of 31 May 2025 | 5.61m | 2.34% |
